Please assess the completion status of the following clinical trial:

Trial Title: Combined Nutritional Therapies for the Treatment of Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients (from 18 to 65 years old) diagnosed with ulcerative colitis (not distal), of at least 1 year of evolution of the disease.~2. Patient in clinical remission two months prior to inclusion (Simple Colitis Clinical Activity Index (SCCAI) \<4) and fecal calprotectin \<150 μg / g.~3. At least one outbreak in the last year that required systemic corticosteroids or escalating treatment (initiation of thiopurines, optimization of thiopurines, initiation of anti-TNF-alpha, intensification of anti-TNF-alpha, initiation of vedolizumab). At the time of entry into the study, the patient must carry with stable medication at least 2 months in the case of anti-TNF-alpha and mesalazine and 5 months in the case of thiopurine, and without treatment with corticosteroids~Exclusion Criteria:~* Patients with ulcerative proctitis only~* Patients who have received antibiotics the month prior to inclusion until completion~* Usual consumption of probiotics excluding fermented milk (yogurt, kefir ...).~* Supplementation with dietary fiber (without taking into account the one administered in the study).~* The smoking habit is allowed, although the beginning or abandonment of it from two months before the end of the study will have to be documented.~* Patients undergoing hypocaloric diets~* Patients with stenosis or intestinal surgery~* Patients with primary sclerosing cholangitis~* Patients under treatment with ursodeoxycholic acid~* Patients under treatment with ion exchange resins~* Patients under treatment with acenocoumarol (Sintrom)~* The taking of proton pump inhibitors (PPIs) is allowed but their consumption must be controlled, not allowing them to start or suspend their intake during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A: 1 dosis (Type: ACTIVE_COMPARATOR): 1 dosis (3E+09 cfu/day + 6 g of fiber/day)
- B: 2 dosis (Type: ACTIVE_COMPARATOR): 2 dosis (3E+09 cfu/day + 12 g of fiber/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).